Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Zarkin GA, Bray JW, Davis KL, Babor TF, Higgins-Biddle JC. The costs of screening and brief intervention for risky alcohol use. J Stud Alcohol. 2003 Jan 1;64(6):849-57.
Lovas K, Geher P, Whalley D, McKenna S, Meads D, Kalo Z. Hungarian adaptation of a disease-specific quality-of-life questionnaire in patients with ankylosing spondylitis. Orv Hetil. 2002 Aug 11;43(32):1893-7.